Research and development - Press Releases

Date	Title	Company
16-Mar-2022	Astellas and We are Pioneer Group (WAPG) Award Future Innovator Prize to Innovative Life Science Startup ImmTune Therapies	Astellas
14-Mar-2022	CSD-Materials suite provides a cohesive analysis of solid form properties for early-phase drug discovery	Cambridge Crystallographic Data Centre (CCDC)
08-Mar-2022	Rapid Microbial Methods, Contamination Control, Sterility Assurance and Environmental Monitoring to be covered at Microbiology East Coast Conference in Boston	SMi Group
08-Mar-2022	AstraZeneca to accelerate global R&D activities for rare diseases with new Development Hub in Barcelona	Alexion, AstraZeneca rare Disease
08-Mar-2022	Alfa Chemistry Materials Presents Itself as a New Supplier of Biomaterials	Alfa Chemistry
05-Mar-2022	Exclusive Chemaxon Interview released - Sponsor at AI in Drug Discovery Conference 2022	SMi Group
03-Mar-2022	CD Formulation: A Supplier of Binder Excipients for Pharmaceutical Preparation	CD Formulation
01-Mar-2022	AARDEX Group Joins Innovative IT4Anxiety Project	AARDEX
01-Mar-2022	CD Formulation Announces Ability to Achieve Solubility Improvement and Bioavailability Enhancement for Drug Formulation Projects	CD Formulation
28-Feb-2022	mdgroup to partner with ERGOMED on new Rare Disease Innovation Center	mdgroup
26-Feb-2022	CD BioSciences Introduces Mutagenesis Services for GPCR Research	CD BioSciences
26-Feb-2022	CD BioSciences Introduces Cell Death Solutions for Bio-research	CD BioSciences
26-Feb-2022	Amerigo Scientific Announces the New Offering of 2-Aminonicotinamide	Amerigo Scientific
26-Feb-2022	STEMart Releases Subacute & Subchronic Toxicity Service for Medical Device Industry	STEMart
26-Feb-2022	CD Bioparticles Launches Ficolls to Support Bio-research	CD Bioparticles
26-Feb-2022	CD Bioparticles Launches Conjugated Gold Nanostars for Research Use	CD Bioparticles
26-Feb-2022	Creative Diagnostics Introduces the Launch of Recombinant Helicobacter Pylori Antigens	Creative Diagnostics
23-Feb-2022	New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA®▼ (guselkumab) at 12 Weeks	Janssen
23-Feb-2022	Results of Novel Clinical Study Show Adults with Moderately to Severely Active Ulcerative Colitis Achieved Higher Rates of Clinical Response, Clinical Remission, and Endoscopic Improvement at 12 Weeks with Guselkumab▼ and Golimumab Combination Therapy Versus Either Monotherapy Alone	Janssen
23-Feb-2022	The Majority of Adults with Moderately to Severely Active Crohn’s Disease in a Phase 2 Study Achieved Clinical Remission and Corticosteroid-Free Remission Through 48 Weeks with TREMFYA®▼ (guselkumab)	Janssen